I-DXd BLA Withdrawal Resets ES-SCLC Timeline: Phase 3 Now the Only Path Through a Graveyard of Prior Failures

Daiichi Sankyo and Merck Withdraw Ifinatamab Deruxtecan BLA

Daiichi Sankyo and Merck have voluntarily withdrawn the Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) in the U.S. for adult patients with extensive-stage small cell lung cancer (ES-SCLC) who experienced disease progression on or after platinum-based chemotherapy. This decision followed discussions with the U.S. FDA, which indicated that data, including from the Phase 2 IDeate-Lung01 trial, did not meet the requirements for accelerated approval for the proposed indication. Despite the withdrawal, patient enrollment is nearing completion for the Phase 3 IDeate-Lung02 trial, which is evaluating ifinatamab deruxtecan against physician's choice chemotherapy in relapsed ES-SCLC patients, with future regulatory filings anticipated based on those results.

• The Biologics License Application (BLA) for ifinatamab deruxtecan in extensive-stage small cell lung cancer was voluntarily withdrawn after discussions with the U.S. FDA. The FDA determined that the supporting data, primarily from the Phase 2 IDeate-Lung01 trial, did not satisfy the requirements needed to support an accelerated approval for the proposed indication, leading to the companies' decision to pull the application.
• Despite the BLA withdrawal, the clinical development program for ifinatamab deruxtecan continues with the Phase 3 IDeate-Lung02 trial, which is nearing completion of enrollment. This trial is evaluating the drug's efficacy and safety against standard chemotherapy options in patients with relapsed ES-SCLC, with future regulatory filings anticipated based on these results.
• Ifinatamab deruxtecan is an investigational B7-H3 directed antibody-drug conjugate (ADC) utilizing Daiichi Sankyo’s proprietary DXd ADC Technology. It has received Orphan Drug Designation from the U.S. FDA, European Commission, Japan Ministry of Health, Labor and Welfare, and Taiwan Food and Drug Administration for SCLC, and from the FDA for esophageal cancer, highlighting its potential in rare and difficult-to-treat cancers.

Why Ifinatamab Deruxtecan's BLA Was Withdrawn for ES-SCLC

Several recent clinical trials have advanced the understanding of first-line and subsequent treatment strategies for ES-SCLC. The ASTRUM-005 phase 3 randomized clinical trial evaluated serplulimab (4.5 mg/kg intravenously) combined with carboplatin and etoposide every 3 weeks for up to 4 cycles in previously untreated patients. At a median follow-up of 42.4 months, the serplulimab group demonstrated a median OS of 15.8 months (95% CI, 13.9–17.4) versus 11.1 months (95% CI, 10.0–12.4) in the placebo group (hazard ratio, 0.60; 95% CI, 0.49–0.73; P < .001), with 4-year OS rates of 21.9% versus 7.2%, respectively. Grade 3 or higher treatment-emergent adverse events occurred in 35.0% of patients in the serplulimab group. The MATCH trial investigated low-dose radiotherapy (15 Gy in 5 fractions) concurrent with atezolizumab (1200 mg) plus cisplatin or carboplatin and etoposide, followed by atezolizumab maintenance, in treatment-naïve ES-SCLC patients. At a median follow-up of 36.1 months, the confirmed ORR was 87.5% (95% CI, 75.9–94.8), median PFS was 6.9 months (95% CI, 5.4–9.3), and median OS was 16.9 months (95% CI, 14.0–32.9). The most common grade 3–5 treatment-related adverse events were decreased neutrophil count (60.7%) and decreased white blood cell count (58.9%).

The SAKK 15/19 trial assessed consolidative thoracic radiotherapy (39 Gy in 13 fractions) following carboplatin AUC5, etoposide 100 mg/m², and durvalumab 1500 mg for 4 cycles, with subsequent durvalumab maintenance every 4 weeks for up to 2 years, in ES-SCLC patients with ECOG ≤ 1. At 29-month follow-up across 46 enrolled patients, the 12-month progression-free rate was 15.6% (95% CI, 7–27.5), median PFS was 6.4 months (95% CI, 4.8–7.2), and median OS was 15.0 months (95% CI, 10.2–22.0). The study did not meet its primary endpoint of a 12-month PFR ≥ 25%. Grade 3–4 treatment-related adverse events occurred in 23.9% of patients, predominantly neutropenia (23.9%) and thrombocytopenia (8.4%), with one grade 5 sepsis event. A separate multicenter phase 2 trial evaluated hypofractionated thoracic radiotherapy concurrent with atezolizumab plus carboplatin/cisplatin and etoposide (the HFRT immunochemotherapy study, NCT04636762) in 40 ES-SCLC patients. At a median follow-up of 14.2 months, median PFS was 8.6 months (95% CI, 6.1–11.1). Grade 3–4 adverse events included decreased neutrophil count, anemia, pneumonitis, esoenteritis, and decreased white cell count, with a pneumonitis rate of 12.5%.

A real-world multicenter retrospective study conducted in China evaluated atezolizumab combined with etoposide/platinum versus etoposide/platinum alone in 225 ES-SCLC patients. The atezolizumab group (n = 133) achieved a median PFS of 7.10 months (95% CI, 6.53–9.00) compared with 6.50 months (95% CI, 4.83–7.53) in the EP-alone group (n = 92), with an overall hazard ratio of 0.69 (95% CI, 0.49–0.97; P = 0.029). Among patients receiving atezolizumab maintenance, the hazard ratio improved to 0.33 (95% CI, 0.20–0.56). Bone marrow suppression was the most common adverse event in the atezolizumab group (58.6%), and immune-related adverse events occurred in 14.3% of patients, with one case of grade 3 encephalitis.

The Persistent Challenges in Treating Extensive-Stage SCLC

Extensive-stage small cell lung cancer (ES-SCLC) remains one of oncology's most formidable challenges, defined by rapid progression, early distant metastasis, high recurrence rates, and a 5-year survival rate of less than 7%. While first-line chemoimmunotherapy has advanced the standard of care, virtually all patients develop resistance and relapse, making durable disease control an elusive goal.

• Universal relapse after first-line therapy: Virtually all ES-SCLC patients develop resistance to first-line platinum-based chemoimmunotherapy, necessitating second-line treatment as an integral part of the treatment paradigm. Despite objective response rates of approximately 60–70% with first-line immunochemotherapy, durable response rates remain only 10–20%.

• Limited and toxic second-line options: Established second-line regimens carry significant drawbacks. Topotecan provides modest clinical benefit and carries the potential for dose-limiting haematological toxicities. Cyclophosphamide-doxorubicin-vincristine combination therapy offers no clear advantages over topotecan. Platinum rechallenge, while more effective and better tolerated than topotecan, is appropriate only in suitable patients and consumes a treatment option that may be needed later.

• Complex and immunosuppressive tumour microenvironment: The limited efficacy of immune combination therapy is driven by SCLC's complex and heterogeneous immune microenvironment, where a network of immunosuppressive factors orchestrates an immune-excluded or "cold" phenotype, restricting the benefit of immune checkpoint inhibitors across patient subgroups.

• CNS progression as a persistent threat: Brain metastases occur frequently and represent a significant threat to quality of life. Although the atezolizumab plus etoposide and carboplatin (AECb) regimen demonstrated a significantly prolonged median time to intracranial progression compared to conventional chemotherapy (24.4 vs. 14.3 months; p = 0.038), CNS progression remains a major clinical concern, and the role of prophylactic cranial irradiation in the era of systematic brain imaging and modern chemoimmunotherapy continues to be reassessed.

• Absence of validated predictive biomarkers: Efficacy of PD-L1 inhibitor-based regimens varies across trials and patient populations — as illustrated by divergent outcomes in IMpower133 and CASPIAN versus KEYNOTE-604 and CheckMate 331 — underscoring the need for refined patient selection strategies and validated biomarkers to guide treatment decisions.

• Rare but severe treatment-emergent toxicities: Emerging agents introduce novel safety risks. Tarlatamab, for instance, has been associated with fatal tumour lysis syndrome even following a single 1-mg step-up dose in patients with high tumour burden, such as those with extensive liver metastases, highlighting the need for careful monitoring and aggressive prophylactic strategies.

Ifinatamab Deruxtecan's Ongoing Clinical Development Program

Beyond extensive-stage small cell lung cancer, ifinatamab deruxtecan (I-DXd) is under active clinical investigation across a range of solid tumour indications, reflecting the broad expression of its B7-H3 target. Evidence from early- and late-phase trials spans both dedicated tumour-type studies and pan-tumour basket designs.

The knowledge base does not have sufficient information on this aspect.

I-DXd's SCLC Strategy Pivots to Phase 3

Small cell lung cancer (SCLC) remains one of oncology's most formidable challenges, characterized by rapid progression, early metastasis, and an almost inevitable relapse after initial therapy. Despite advances with first-line chemoimmunotherapy, the prognosis for patients with extensive-stage disease who progress remains poor, underscoring a critical unmet medical need. It is within this landscape that ifinatamab deruxtecan (I-DXd), a B7-H3-directed antibody-drug conjugate (ADC), emerged as a promising candidate, demonstrating encouraging efficacy, including intracranial activity, and a manageable safety profile in early-phase trials like IDeate-Lung01.

The recent voluntary withdrawal of I-DXd's Biologics License Application for accelerated approval in the U.S. for relapsed ES-SCLC, following discussions with the FDA, signals a strategic recalibration. This decision highlights the regulatory body's stringent requirements for accelerated approval, particularly when relying on Phase 2 data, even for therapies targeting aggressive diseases. While a setback for immediate market entry, it redirects focus to the ongoing Phase 3 IDeate-Lung02 trial, which is designed to provide the robust, confirmatory data needed for traditional approval. This pivotal study compares I-DXd against physician's choice chemotherapy (topotecan, amrubicin, or lurbinectedin), aiming to definitively establish its superiority in a larger, more diverse patient population.

The success of IDeate-Lung02 is paramount. The trial faces the inherent risk that I-DXd may not demonstrate a statistically significant improvement in its dual primary endpoints of objective response rate and overall survival against existing second-line options. Furthermore, while the safety profile in Phase 2 was manageable, the larger Phase 3 cohort could reveal a different incidence or severity of adverse events, such as interstitial lung disease, which was observed in 12.4% of patients in IDeate-Lung01. The broader SCLC landscape also presents challenges, including the disease's molecular heterogeneity and the 'target-modality problem,' where the delivery mechanism (e.g., ADC vs. bispecific T-cell engager) can significantly impact therapeutic success, as seen with DLL3-targeted agents. Despite these hurdles, the continued development of I-DXd underscores the potential of B7-H3 as a therapeutic target and the ongoing pursuit of more effective, targeted therapies for this devastating cancer. The outcome of IDeate-Lung02 will be a critical determinant of I-DXd's future and a significant indicator for the broader ADC development strategy in SCLC.